Literature DB >> 17947943

[Papillary thyroid microcarcinoma. Long-term outcome in 587 cases compared with published data].

M R Pelizzo1, I Merante Boschin, A Toniato, A Piotto, P Bernante, C Pagetta, E Casal Ide, R Mazzarotto, D Casara, D Rubello.   

Abstract

AIM: Papillary thyroid microcarcinoma (PTMC), a tumor measuring =or<1 cm according to the World Health Organization (WHO) histologic classification, is the most common histologic variant of thyroid cancer. The aim of this study was to evaluate the long-term outcome of surgical treatment for PTMC at a single institution with a view to differentiate therapy options based on risk of progression of disease by comparing our results with those reported in the literature.
METHODS: The study sample was a total of 587 cases of PTMC treated surgically at our institution between 1990 and 2006. PTMC was an incidental finding (PTMC-I) in 325 (55.4%) cases, diagnosed preoperatively (PTMC-D) at echography and needle-aspiration biopsy in 229 (39%), and occult with metastasis (PTMC-O) in 33 (5.6%). Patients were grouped into two classes (PTMC diameter =or>5 mm or <5 mm) and compared against prognostic factors: sex, age, type of PTMC (PTMC-I, PTMC-D, PTMC-O), extent of surgery, lymph node dissection, lymph node metastasis, iodine-131 (131-I) therapy, state of disease, relapses. These parameters were then compared against tumor size (PTMC diameter =or>5 mm or <5 mm), excluding cases of PTMC-O with metastasis.
RESULTS: Comparison of the two groups divided by tumor size, across the entire sample and after PTMC-O cases were excluded, revealed significant differences in the type of PTMC, frequency of partial thyroidectomy, presence of lymph node metastasis, iodine-131 therapy, life status and recurrence rate.
CONCLUSION: Published PTMC studies were analyzed for definition of the disease, incidence, therapy, prognosis, and follow-up results and compared with our data. The results of our analysis argue against use of the term ''microcarcinoma'' in the wider sense since the three PTMC categories (PTMC-I, PTMC-D, PTMC-O) present different behaviour patterns. When cases of PTMC-O with clinically manifest metastasis were excluded, none of the patients with PTMC <5 mm in diameter were reoperated for tumor recurrence and all are currently free of disease. In conclusion In PTMC <5 mm in diameter, whether PTMC-I and PTMC-D, and without evidence of lymph node involvement, partial thyroidectomy may be a viable approach to treatment. By contrast, occult PTMC with metastasis is prognostically important and should therefore be treated like tumors =or>5 mm in diameter.

Entities:  

Mesh:

Year:  2007        PMID: 17947943

Source DB:  PubMed          Journal:  Minerva Chir        ISSN: 0026-4733            Impact factor:   1.000


  6 in total

1.  Tescalcin promotes highly invasive papillary thyroid microcarcinoma by regulating FOS/ERK signaling pathway.

Authors:  Xiuhe Zou; Qian Zhou; Yan Nie; Junhe Gou; Jing Yang; Jingqiang Zhu; Zhihui Li; Yanping Gong
Journal:  BMC Cancer       Date:  2022-05-31       Impact factor: 4.638

2.  Prognostic values of thyroid tumours.

Authors:  Suzana Manxhuka-Kerliu; Emine Devolli-Disha; Arsim Gerxhaliu; Halil Ahmetaj; Arijeta Baruti; Sadushe Loxha; Hajdin Thaqi
Journal:  Bosn J Basic Med Sci       Date:  2009-05       Impact factor: 3.363

3.  Multicentricity Is More Common in Thyroid Papillary Microcancer with a Preoperative Diagnosis Compared to Incidental Microcancer.

Authors:  Yalin Iscan; Ismail Cem Sormaz; Fatih Tunca; Yasemin Giles Senyurek
Journal:  Eur Thyroid J       Date:  2019-08-07

Review 4.  Geographic influences in the global rise of thyroid cancer.

Authors:  Jina Kim; Jessica E Gosnell; Sanziana A Roman
Journal:  Nat Rev Endocrinol       Date:  2019-10-15       Impact factor: 43.330

5.  Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience [corrected].

Authors:  Khalid Hussain Al-Qahtani; Mushabbab Al Asiri; Mutahir A Tunio; Naji J Aljohani; Yasser Bayoumi; Hanadi Fatani; Abdulrehman AlHadab
Journal:  J Otolaryngol Head Neck Surg       Date:  2015-12-01

6.  Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma - Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015.

Authors:  Agnieszka Czarniecka; Marcin Zeman; Grzegorz Wozniak; Adam Maciejewski; Ewa Stobiecka; Ewa Chmielik; Malgorzata Oczko-Wojciechowska; Jolanta Krajewska; Daria Handkiewicz-Junak; Barbara Jarzab
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-06       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.